Comparative study of poliovirus excretion after vaccination of infants with two oral polio vaccines prepared on vero cells or on primary monkey kidney cells

Journal of Medical Virology

Volumn 52, Issue 1, 1997, Pages 50-60

  Mallet, L ^a   Pelloquin, F ^a,d   Brigaud, M ^b   Caudrelier, P ^a   Bandet, R ^a   Xueref, C ^a   Fuchs, F ^b   Gibelin, N ^a   Goldman, C ^a   Moulin, J C ^a   De Fraipont, F ^a,c   Montagnon, B ^a   Peyron, L ^a   Aymard, M ^b  

^a Pasteur Merieux Serums et Vaccins   (France)

^b Centre National de Reference des Staphylocoques   (France)

^c CNRS   (France)

^d Quality Controls   (Belgium)

Author keywords

direct detection; nested PCR, stool; neurovirulence; poliovirus; reversion

Indexed keywords

ORAL POLIOMYELITIS VACCINE;

ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FECES ANALYSIS; FRANCE; HUMAN; INFANT; MAJOR CLINICAL STUDY; ORAL DRUG ADMINISTRATION; POLIOMYELITIS; POLIOMYELITIS VIRUS; POLYMERASE CHAIN REACTION; SEROCONVERSION; VACCINATION; VIRUS CULTURE; VIRUS DETECTION;

ANIMALS; ANTIBODIES, VIRAL; CELL LINE; CERCOPITHECUS AETHIOPS; CLONING, MOLECULAR; FECES; GENOTYPE; HUMANS; INFANT; MACACA FASCICULARIS; MACACA MULATTA; NEUTRALIZATION TESTS; PILOT PROJECTS; POLIOMYELITIS; POLIOVIRUS; POLIOVIRUS VACCINE, ORAL; POLYMERASE CHAIN REACTION; SEROTYPING; VACCINATION; VERO CELLS; VIRULENCE; VIRUS SHEDDING;

POLIOVIRUS;

EID: 0031008102     PISSN: 01466615     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1096-9071(199705)52:1<50::AID-JMV9>3.0.CO;2-Q     Document Type: Article

References (49)

1. Abraham R, Minor P, Dunn G, Modlin JF, Ogra PL (1993): Shedding of virulent revertants during immunization with oral poliovirus vaccine after prior immunization with inactivated polio vaccine. Journal of Infectious Diseases 168:1105-1109.
2. Cammack N, Phillips A, Dunn G, Patel V, Minor PD (1988): Intertypic genomic rearrangements of poliovirus strains in vaccinees. Virology 167:507-514.
3. Cann AJ, Stanway G, Hugues PJ, Minor PD, Evans DMA, Schild GC, Almond JW (1984): Reversion to neurovirulence of the live-attenuated Sabin type 3 oral poliovirus vaccine. Nucleic Acids Research 12:7787-7792.
4. Chumakov KM, Powers LB, Noonan KE, Roninson LB, Levenbook IS (1991): Correlation between amount of virus with altered nucleotide sequence and the monkey test for acceptability of oral poliovirus vaccine. Proceedings of the National Academy of Sciences USA 88:199-203.
5. Chumakov KM, Norwood LP, Parker ML, Dragunsky EM, Ran Y, Levenbook IS (1992): RNA sequence variants in live poliovirus vaccine and their relation to neurovirulence. Journal of Virology 66:966-970.
6. Crainic R, Couillin P, Blondel B, Cabau N, Boue A, Horodniceanu F (1983): Natural variation of poliovirus neutralization epitopes. Infection and Immunity 41:1217-1225.
7. De Filippis AMB, Schatzmayr HG, Ferreira FC, Chagas SAR, Costa MC, Santos AP, Da Silva EE (1994): Intratypic differentiation of polioviruses isolated from suspected cases of poliomyelitis in Brazil during the period of 1990 to 1993. Memorial of the Institute Oswaldo Cruz 89:513-518.
8. Dulbecco R, Vogt M (1954): Plaque formation and isolation of pure lines with poliomyelitis viruses. Journal of Experimental Medicine 99:167-182.
9. Dunn G, Begg NT, Cammack W, Minor PD (1990): Virus excretion and mutation by infants following primary vaccination with live oral poliovaccine from two sources. Journal of Medical Virology 32:92-95.
10. Equestre M, Genovese D, Cavalieri F, Fiore L, Santoro R, Perez Bercoff R (1991): Identification of a consistent pattern of mutations in neurovirulent variants derived from the Sabin vaccine strain of poliovirus type 2. Journal of Virology 65:2707-2710.
11. Evans DMA, Dunn G, Minor PD, Schild GC, Cann AJ, Stanway G, Almond JW, Currey K, Maizel Jr. JV (1985): Increased neurovirulence associated with a single nucleotide change in a noncoding region of the Sabin type 3 poliovaccine genome. Nature 314:548-550.
12. Faden H, Modlin JF, Thoms ML, McBean AM, Ferdon MB, Ogra PL (1990): Comparative evaluation of immunization with live attenuated and enhanced potency inactivated trivalent poliovirus vac-cines in childhood: Systemic and local immune responses. Journal of Infectious Diseases 162:1291-1297.
13. Finney AJ (1978): "Statistical Method in Biological Assay," 3rd ed. London: Charles Griffin & Company, Ltd.
14. Furione M, Guillot S, Otelea D, Balanant J, Candrea A, Crainic R (1993): Polioviruses with natural recombinant genomes isolated from vaccine-associated paralytic poliomyelitis. Virology 196:199-208.
15. Higuchi HG, Ochman H (1989): Production of single-stranded DNA templates by exonuclease digestion following the polymerase chain reaction. Nucleic Acids Research 17:5865.
16. Kawamura N, Kohara M, Abe S, Komatsu T, Tago K, Arita M, Nomoto A (1989): Determinants in the 5′ noncoding region of poliovirus Sabin 1 RNA, that influence the attenuation phenotype. Journal of Virology 63:1302-1309.
17. Kew OM, Nottay BK (1984): Evolution of the oral polio vaccine in humans occurs by both mutation and intramolecular recombination. In Chanock RM and Lerner RA (eds), "Modern Approaches to Vaccines: Molecular and Chemical Basis of Virus Virulence and Immunogenicity." Cold Spring Harbor, NY: Cold Spring Harbor Laboratory, pp. 357-362.
18. Leparc I, Fuchs F, Kopecka H, Aymard M (1993): Use of the polymerase chain reaction with a murine model of picornavirus-induced myocarditis. Journal of Clinical Microbiology. 31:2890-2894.
19. Lu Z, Douthitt MP, Taffs RE, Ran Y, Norwood LP, Chumakov KM (1993): Quantitative aspects of the mutant analysis by PCR and restriction enzyme cleavage (MAPREC). PCR Methods and Applications 3:176-180.
20. Macadam AJ, Arnold C, Hewlett J, John A, Marsden S, Taffs F, Reeve P, Hamada N, Wareham K, Almond J, Cammack N, Minor PD (1989): Reversion of the attenuated and temperature-sensitive phenotypes of the Sabin type 3 strain of poliovirus in vaccinees. Virology 172:408-414.
21. Macadam AJ, Pollard SA, Ferguson G, Skuce R, Wood D, Almond JW, Minor PD (1993): Genetic basis of attenuation of the Sabin type 2 vaccine strain of poliovirus in primates. Virology 192:18-26.
22. Minor PD, John A, Ferguson M, Icenogle JP (1986): Antigenic and molecular evolution of the vaccine strain of type 3 poliovirus during the period of excretion by a primary vaccinee. Journal of General Virology 67:693-706.
23. Minor PD, Dunn G (1988): The effect of sequences in the 5′ non-coding region on the replication of polioviruses in the human gut. Journal of General Virology 69:1091-1096.
24. Minor PD (1992): The molecular biology of poliovaccines. Journal of General Virology 73:3065-3077.
25. Montagnon BJ (1989): Polio and rabies vaccines produced in continuous cell lines: a reality for Vero cell lines. Developments in Biological Standardization 70:27-47.
26. Muzychenko AR, Lipskaya GY, Maslova S, Svitkin YV, Pilipenko EV, Nottay BK, Kew OM, Agol VI (1991): Coupled mutations in the 5′-untranslated region of the Sabin poliovirus strain during in vivo passages: structure and functional implications. Virus Research 21:111-122.
27. Netter R, Celers J, Cassaigne R, Brigaud M (1982): La poliomyélite en France en 1980. Bulletin de l'Académie Nationale de Médecine 166:809-817.
28. Nkowane BM, Wassilak SGF, Orenstein WA, Bart KJ, Schonberger LB, Hinman AR, Kew OM (1987): Vaccine-associated paralytic poliomyelitis. Journal of the American Medical Association 257: 1335-1340.
29. Otelea D, Guillot S, Furione M, Combiescu AA, Balanant J, Candrea A, Crainic R (1993): Genomic modifications in naturally occurring neurovirulent revertants of Sabin 1 polioviruses. Developments in Biological Standardization 78:33-38.
30. Patriarca PA, Wright PF, Jacob John T (1991): Factors affecting the immunogenicity of oral poliovirus vaccine in developing countries: review. Reviews of Infectious Diseases 13:926-939.
31. Pollard SR, Dunn G, Cammack N, Minor PD, Almond JW (1989): Nucleotide sequence of a neurovirulent variant of the type 2 oral poliovirus vaccine. Journal of Virology 63:4949-4951.
32. Prevots DR, Sutter RW, Strebel PM, Weibel RE, Cochi SL (1994): Completeness of reporting for paralytic poliomyelitis, United States, 1980 through 1991. Implications for estimating the risk of vaccine-associated disease. Archives of Pediatric and Adolescent Medicine 148:479-485.
33. Reed LJ, Muench H (1938): A simple method for estimating fifty percent end points. American Journal of Hygiene 27:493-497.
34. Rezapkin GV, Chumakov KM, Lu Z, Ran Y, Dragunsky EM, Levenbook IS (1994): Microevolution of Sabin 1 strain in vitro and genetic stability of oral poliovirus vaccine. Virology 202:370-378.
35. Roure C, I. Rebiere I, Aymard M, Dubrou S (1991): Surveillance de la poliomyélite en France. Bulletin Epidémiologique Hebdomadaire 15:59-61.
36. Roure C (1991): Elimination of poliomyelitis in France. WHO consultation on surveillance in Europe, Veyrier-du Lac, 26-27 August 1991. ICP/EPI 028/16 1315n, 16 August 1991.
37. Sabin AB, Boulger LR (1973): History of Sabin attenuated poliovirus oral live vaccine strains. Journal of Biological Standardization 1: 115-118.
38. Salk J, Salk D (1977): Control of influenza and poliomyelitis with killed virus vaccines. Science 195:834-837.
39. Sanger F, Nicklen S, Coulson AR (1977): DNA sequencing with chain-terminating inhibitors. Proceedings of the National Academy of Sciences USA 74:5463-5467.
40. Snedecor GW, Cochran WG (1957): "Statistical Methods," 6th ed. Ames, Iowa: The Iowa State University Press Ames.
41. Strebel PM, Sutter RW, Cochi SL, Biellik RJ, Brink EW, Kew OM, Pallansch MA, Orenstein WA, Hinman AR (1992): Epidemiology of poliomyelitis in the United States one decade after the last reported case of indigenous wild virus-associated disease. Clinical Infectious Diseases 14:568-579.
42. Taffs RE, Chumakov KM, Rezapkin GV, Lu Z, Douthitt M, Dragunsky EM, Levenbook IS (1995): Genetic stability and mutant selection in Sabin 2 strain of oral poliovirus vaccine grown under different cell culture conditions. Virology 209:366-373.
43. Tatem JM, Weeks-Levy C, Mento SJ, DiMichele SJ, Georgiu A, Waterfield WF, Sheip B, Costalas C, Davies T, Ritchey MR, Cano FR (1991): Oral poliovirus vaccine in the United States: Molecular characterization of Sabin type 3 after replication in the gut of vaccinees. Journal of Medical Virology 35:101-109.
44. Toyoda H, Kohara M, Kataoka Y, Suganuma T, Omata T, Imura N, Nomoto A (1984): Complete nucleotide sequence of all three poliovirus serotype genomes. Journal of Molecular Biology 174:561-585.
45. Tulchinsky T, Abed Y, Handser R, Toubassi N, Acker C, Melnick J (1994): Successful control of poliomyelitis by a combined OPV/IPV polio vaccine program in the West Bank and Gaza, 1978-93. Israel Journal of Medical Sciences 30:489-494.
46. Vincent-Falquet JC, Peyron L, Souvras M, Moulin JC, Tektoff J, Patet J (1989): Qualification of working cell banks for the Vero cell line to produce licensed human vaccines. Developments in Biological Standardization 70:153-156.
47. Von Magnus H, Petersen L (1984): Vaccination with inactivated poliovirus vaccine and oral poliovirus vaccine in Denmark. Reviews of Infectious Diseases 6:S471-S474.
48. Westrop GD, Wareham KA, Evans DMA, Dunn G, Minor PD, Magrath DI, Taffs F, Marsden S, Skinner MA, Schild GC, Almond JW (1989): Genetic basis of attenuation of the Sabin type 3 oral poliovirus vaccine. Journal of Virology 63:1338-1344.
49. WHO (1990): Requirements for poliomyelitis vaccine (oral). World Health Organization Technical Report Series 800:30-65.